Insulet ROA 2010-2025 | PODD
Current and historical return on assets (ROA) values for Insulet (PODD) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Insulet ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-03-31 | $0.40B | $3.52B | 12.88% |
| 2024-12-31 | $0.42B | $3.09B | 14.46% |
| 2024-09-30 | $0.42B | $3.03B | 15.18% |
| 2024-06-30 | $0.40B | $2.88B | 15.00% |
| 2024-03-31 | $0.23B | $2.62B | 9.30% |
| 2023-12-31 | $0.21B | $2.59B | 8.47% |
| 2023-09-30 | $0.12B | $2.47B | 5.11% |
| 2023-06-30 | $0.06B | $2.39B | 2.77% |
| 2023-03-31 | $0.00B | $2.29B | 0.05% |
| 2022-12-31 | $0.00B | $2.25B | 0.23% |
| 2022-09-30 | $0.02B | $2.17B | 0.81% |
| 2022-06-30 | $0.04B | $2.11B | 1.70% |
| 2022-03-31 | $0.05B | $2.07B | 2.24% |
| 2021-09-30 | $-0.03B | $2.00B | -1.52% |
| 2021-06-30 | $-0.03B | $1.92B | -1.63% |
| 2020-12-31 | $0.01B | $1.87B | 0.44% |
| 2020-09-30 | $0.03B | $1.71B | 2.08% |
| 2020-06-30 | $0.02B | $1.63B | 1.40% |
| 2020-03-31 | $0.01B | $1.11B | 0.44% |
| 2019-12-31 | $0.01B | $1.14B | 1.01% |
| 2019-09-30 | $0.02B | $1.27B | 1.55% |
| 2019-06-30 | $0.02B | $0.98B | 1.82% |
| 2019-03-31 | $0.01B | $0.95B | 1.55% |
| 2018-12-31 | $0.00B | $0.93B | 0.34% |
| 2018-09-30 | $-0.01B | $0.89B | -1.66% |
| 2018-06-30 | $-0.02B | $0.84B | -2.41% |
| 2018-03-31 | $-0.02B | $0.83B | -3.68% |
| 2017-12-31 | $-0.03B | $0.82B | -4.86% |
| 2017-09-30 | $-0.03B | $0.50B | -6.23% |
| 2017-06-30 | $-0.03B | $0.46B | -6.62% |
| 2017-03-31 | $-0.03B | $0.45B | -6.43% |
| 2016-12-31 | $-0.03B | $0.46B | -7.84% |
| 2016-09-30 | $-0.05B | $0.45B | -14.77% |
| 2016-06-30 | $-0.06B | $0.26B | -22.84% |
| 2016-03-31 | $-0.07B | $0.26B | -26.00% |
| 2015-12-31 | $-0.07B | $0.28B | -24.87% |
| 2015-09-30 | $-0.05B | $0.29B | -17.06% |
| 2015-06-30 | $-0.04B | $0.30B | -14.29% |
| 2015-03-31 | $-0.06B | $0.31B | -18.55% |
| 2014-12-31 | $-0.05B | $0.30B | -16.83% |
| 2014-09-30 | $-0.05B | $0.30B | -16.29% |
| 2014-06-30 | $-0.06B | $0.33B | -19.82% |
| 2014-03-31 | $-0.04B | $0.29B | -14.24% |
| 2013-12-31 | $-0.05B | $0.29B | -16.08% |
| 2013-09-30 | $-0.05B | $0.29B | -20.11% |
| 2013-06-30 | $-0.04B | $0.29B | -18.18% |
| 2013-03-31 | $-0.05B | $0.28B | -21.22% |
| 2012-12-31 | $-0.05B | $0.20B | -24.85% |
| 2012-09-30 | $-0.06B | $0.20B | -26.07% |
| 2012-06-30 | $-0.06B | $0.20B | -26.60% |
| 2012-03-31 | $-0.05B | $0.22B | -23.21% |
| 2011-12-31 | $-0.05B | $0.22B | -22.66% |
| 2011-09-30 | $-0.05B | $0.22B | -28.38% |
| 2011-06-30 | $-0.05B | $0.23B | -29.96% |
| 2011-03-31 | $-0.06B | $0.15B | -36.95% |
| 2010-12-31 | $-0.06B | $0.16B | -38.92% |
| 2010-09-30 | $-0.06B | $0.15B | -34.78% |
| 2010-06-30 | $-0.06B | $0.16B | -39.93% |
| 2010-03-31 | $-0.07B | $0.16B | -48.91% |
| 2009-12-31 | $-0.07B | $0.17B | -57.37% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $20.408B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $228.771B | 27.51 |
| Boston Scientific (BSX) | United States | $153.093B | 38.33 |
| Stryker (SYK) | United States | $149.084B | 31.17 |
| EssilorLuxottica (ESLOY) | France | $130.144B | 0.00 |
| Medtronic (MDT) | Ireland | $114.429B | 16.22 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.231B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.710B | 24.95 |
| ResMed (RMD) | United States | $36.952B | 27.75 |
| GE HealthCare Technologies (GEHC) | United States | $34.062B | 16.17 |
| Agilent Technologies (A) | United States | $32.082B | 20.92 |
| Terumo (TRUMY) | Japan | $24.207B | 31.44 |
| Koninklijke Philips (PHG) | Netherlands | $23.216B | 16.29 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.604B | 11.95 |
| Baxter (BAX) | United States | $14.497B | 10.82 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.846B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.731B | 23.42 |
| Lantheus Holdings (LNTH) | United States | $5.622B | 14.18 |
| Perrigo (PRGO) | Ireland | $3.719B | 9.43 |
| Prestige Consumer Healthcare (PBH) | United States | $3.714B | 16.59 |
| Haemonetics (HAE) | United States | $3.585B | 16.33 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.358B | 27.90 |
| ICU Medical (ICUI) | United States | $3.113B | 22.96 |
| QuidelOrtho (QDEL) | United States | $1.890B | 13.00 |
| LeMaitre Vascular (LMAT) | United States | $1.858B | 41.53 |
| AtriCure (ATRC) | United States | $1.512B | 0.00 |
| Acuren (TIC) | United States | $1.407B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.245B | 28.00 |
| Phibro Animal Health (PAHC) | United States | $1.239B | 15.83 |
| AdaptHealth (AHCO) | United States | $1.205B | 12.23 |
| Neogen (NEOG) | United States | $1.079B | 13.81 |
| BioLife Solutions (BLFS) | United States | $0.994B | 0.00 |
| InMode (INMD) | Israel | $0.901B | 9.08 |
| Kestra Medical Technologies (KMTS) | United States | $0.836B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.670B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.660B | 0.00 |
| Owens & Minor (OMI) | United States | $0.600B | 4.98 |
| Evolus (EOLS) | United States | $0.598B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.597B | 0.00 |
| CeriBell (CBLL) | United States | $0.569B | 0.00 |
| Valneva SE (VALN) | France | $0.549B | 0.00 |
| Surmodics (SRDX) | United States | $0.448B | 0.00 |
| SNDL (SNDL) | Canada | $0.397B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.328B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.318B | 11.71 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.285B | 0.00 |
| Quanterix (QTRX) | United States | $0.274B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.262B | 22.07 |
| Cresco Labs (CRLBF) | United States | $0.258B | 0.00 |
| Cerus (CERS) | United States | $0.258B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.252B | 74.83 |
| ZimVie (ZIMV) | United States | $0.246B | 11.19 |
| Sanara MedTech (SMTI) | United States | $0.242B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.233B | 0.00 |
| Brainsway (BWAY) | Israel | $0.231B | 61.00 |
| Biote (BTMD) | United States | $0.216B | 6.06 |
| Omeros (OMER) | United States | $0.212B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.200B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.199B | 0.00 |
| Organigram Global (OGI) | Canada | $0.192B | 0.00 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 14.80 |
| TriSalus Life Sciences (TLSI) | United States | $0.179B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.155B | 0.00 |
| Exagen (XGN) | United States | $0.144B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.124B | 15.25 |
| TerrAscend (TSNDF) | Canada | $0.107B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.099B | 12.80 |
| MacroGenics (MGNX) | United States | $0.094B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Veru (VERU) | United States | $0.085B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.080B | 0.00 |
| Apyx Medical (APYX) | United States | $0.077B | 0.00 |
| Zynex (ZYXI) | United States | $0.069B | 0.00 |
| Agape ATP (ATPC) | $0.069B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.057B | 0.00 |
| United-Guardian (UG) | United States | $0.042B | 14.41 |
| Modular Medical (MODD) | United States | $0.038B | 0.00 |
| Nephros (NEPH) | United States | $0.037B | 50.43 |
| Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
| Safety Shot (SHOT) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.024B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |